medigraphic.com
ISSN 1561-3194 (Electronic)

2020, Number 5

<< Back Next >>

Rev Ciencias Médicas 2020; 24 (5)

The only severely-ill COVID-19 patient reported in Pinar del Río

Cuello CMB, Díaz AH, Ordoñez ALY

Language: Spanish
References: 12
Page: 1-7
PDF size: 190.13 Kb.


ABSTRACT

Introduction: SARS-CoV-2 (COVID-19) is a threat to global public health; with the most negative effect on patients with comorbidities and weak health status.
Clinical case: a 59-year-old, white skinned, female patient with personal pathological history of high blood pressure, diabetes mellitus type II, chronic obstructive pulmonary disease and ex-smoker with confirmed positive PCR-RT (COVID-19 carrier), presented acute inflammatory pneumopathy as a complication and satisfactory evolution. Without a precise source of infection, all contacts were isolated, they underwent to studies and resulted negative to COVID-19.
Conclusions: with this case report it is concluded that this pandemic is a challenge for the scientific community because there is not a specific treatment against SARSCoV-2. Nevertheless, Cuba makes use of its protocols of treatment where diverse medicines are included; which have demonstrated effectiveness in the control of the disease, achieving a satisfactory clinical evolution of several critical patients.


REFERENCES

  1. World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan, China [Internet]. Ginebra: OMS; 2020. [cited 14/04/2020] Available from: Available from: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china

  2. Ministerio de Salud Pública. Parte del cierre del 19 de mayo a las 12 de la noche [Internet]. La Habana: MINSAP; 2020. [cited 14/04/2020] Available from: Available from: https://salud.msp.gob.cu/?cat=839

  3. Centro Nacional de Información de Ciencias Médicas. Actualización epidemiológica. Nuevo coronavirus (2019-nCoV) [Internet]. La Habana: Centro Nacional de Información de Ciencias Médicas; 2020 [Citado 17/04/2020]. Disponible en: Disponible en: https://temas.sld.cu/coronavirus/2020/01/28/nuevo-coronavirus-2019-ncov-actualizacion

  4. Pérez Abreu MR, Gómez Tejeda JJ, Diéguez Guach RA. Características clínico-epidemiológicas de la COVID-19. Rev haban cienc méd [Internet]. 2020 [Citado 25/04/2020]; 19(2): 3254. Disponible en: Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/arti cle/view/3254/2505

  5. Chih Cheng L. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents [Internet]. 2020 Mar [Citado 17/04/2020]; 55(3): [aprox. 4p.]. Disponible en: Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105924

  6. Ministerio de Salud Pública. Protocolo Nacional MINSAP vs COVID-19 [Internet]. La Habana: MINSAP ; 2020 [Citado 10/04/2020]. Disponible en: Disponible en: https://files.sld.cu/sars/files/2020/04/Protocolo-provisional-de-Cuba-vs-COVID-4abril2020.pdf

  7. Cortegiani G, Ingoglia MI. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care [Internet]. 2020 Mar [Citado 20/04/2020]; 57: 279-283. Disponible en: Disponible en: https://doi.org/10.1016/j.jcrc.2020.03.005

  8. Coutard B. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade. Antiviral Research [Internet]. 2020 Apr [Citado 17/05/2020]; 176: [aprox. 3 p.]. Disponible en: Disponible en: https://doi.org/10.1016/j.antiviral.2020.104742

  9. Cao B, Wang Y, Wen D. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med [Internet]. 2020 [Citado 18/04/2020]; 382: 1787-1799. Disponible en: Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa2001282

  10. Gautret P, Lagier JC, Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non randomized clinical trial. Int J Antimicrob Agents [Internet]. 2020 Mar [Citado 17/04/2020]; 56(1): [aprox. 2p.]. Disponible en: Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949

  11. Sanders J, Monogue M , Jodlowski T. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA [Internet]. 2020 April [Citado 17/04/2020]; 323(18): 1824-1836. Disponible en: Disponible en: https://doi.org/10.1001/jama.2020.6019

  12. Huang C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet [Internet]. 2020 [Citado 17/04/2020]; 395(10223): 497-506. Disponible en: Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext




2020     |     www.medigraphic.com